Figure 1.
Current status of TKI therapy for CML. (A) Most approved drugs recognize the binding site for ATP in BCR-ABL, as: Imatinib, Dasatinib, Nilotinib, Bosutinib, and Ponatinib. Asciminib binds to the myristoyl pocket of the BCR-ABL kinase. The new molecules of third and fourth generation TKIs including: Olverembatinib (HQP1351), Vodobatinib (K0706) and PF-114. (B) Omacetaxine is an approved inhibitor that blocks protein synthesis.